Sakamoto, Susumu

Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial

Sakamoto, S., Kataoka, K., Kondoh, Y., Kato, M., Okamoto, M., Mukae, H., Bando, M., Suda, T., Yatera, K., Tanino, Y., et al. (2021) · European Respiratory Journal

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 67

Efficacy of Pirfenidone in Patients with Advanced-stage Idiopathic Pulmonary Fibrosis

Sakamoto, S., Itoh, T., Muramatsu, Y., Satoh, K., Ishida, F., Sugino, K., Isobe, K., & Homma, S. (2013) · Internal Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 59

Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience

Isshiki, T., Sakamoto, S., Yamasaki, A., Shimizu, H., Miyoshi, S., Nakamura, Y., Homma, S., & Kishi, K. (2021) · Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 19

Exploratory phase 2 study of the novel oral multi-kinase inhibitor TAS-115 in patients with idiopathic pulmonary fibrosis

Nishioka, Y., Homma, S., Ogura, T., Sato, S., Arai, N., Tomii, K., Kamio, K., Sakamoto, S., Miyazaki, Y., Tomioka, H., et al. (2023) · Respiratory Investigation

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 12

Japanese guidelines for the treatment of idiopathic pulmonary fibrosis 2023:Revised edition

Bando, M., Homma, S., Date, H., Kishi, K., Yamauchi, H., Sakamoto, S., Miyamoto, A., Goto, Y., Nakayama, T., Azuma, A., et al. (2024) · Respiratory Investigation

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 12